A phase II prospective study evaluating the role of pemetrexed plus gemcitabine (Pem/Gem) chemotherapy as intial treatment in patients with stage IIIB/IV non-small cell lung cancer (NSCLC) using a genomic predictor of cisplatin-resistance to guide therapy


Journal Article

Full Text

Duke Authors

Cited Authors

  • Garst, J; Datto, M; Herndon, JE; Barry, WT; Shoemaker, D; Bjurstrom, A; Andrews, C; Ginsburg, G; Nevins, JR; Potti, A

Published Date

  • May 20, 2008

Published In

Volume / Issue

  • 26 / 15_suppl

Start / End Page

  • 8108 - 8108

Published By

Electronic International Standard Serial Number (EISSN)

  • 1527-7755

International Standard Serial Number (ISSN)

  • 0732-183X

Digital Object Identifier (DOI)

  • 10.1200/jco.2008.26.15_suppl.8108


  • en